CRISPR Therapeutics could start reporting product revenue soon.Vertex Pharmaceuticals (VRTX 0.43%) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more than $9.8 billion in revenue last year. Vertex also recently submitted its latest CF candidate to regulators for consideration -- and an approval could truly cement its long-term dominance.On top of this, late last year Vertex won approval -- along wit ...

KING OF PRUSSIA, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of the ...

KING OF PRUSSIA, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of the ...

AndreyPopovVertex's Investment in Innovation and Rare Disease Leadership Since my last look in December, Vertex's (NASDAQ:VRTX) stock performance has mirrored SPY, up 18%. My focus back then followed Vertex's VX-548 Phase 2 data in diabetic peripheral neuropathy (DPN), in which the oral selective inhibitor of the NaV1.8 sodium channel was on par with the popular and blockbuster neuropathy drug, Lyrica. The company's potential in DPN, among other prospects, including their existing fortress within the cy ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-2081753 ...

Exhibit 99.1 Vertex Announces First Quarter 2024 Financial Results KING OF PRUSSIA, PA – May 8, 2024: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2024. “The year is off to a solid start, and I am very pleased with our financial performance in the first quarter,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “Revenue trac ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-2081753 (State or other jurisd ...

Exhibit 99.1 Vertex Announces Fourth Quarter and Full Year 2023 Financial Results KING OF PRUSSIA, PA – February 29, 2024: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2023. “The Vertex execution engine delivered exceptionally strong financial results in the fourth quarter,” stated David DeStefano, Vertex Chief Executive Officer. “Our year-over-year reven ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-2081753 (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39413 VERTEX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 23-2081753 (State or other ju ...